SB526 H HHR AM #1
CR 3338
The Committee on Health and Human Resources moved to amend bill on page 1, by striking everything after the enacting clause and inserting in lieu thereof the following:
(a) A licensed pharmacist may:
(1) Provide care related to the interpretation, evaluation, and implementation of medical orders;
(2) Dispense of prescription drug orders; participate in drug and device selection;
(3) Provide drug administration;
(4) Provide drug regimen review;
(5) Provide drug or drug-related research;
(6) Perform patient counseling;
(7) Provide pharmacy related primary care;
(8) Provide pharmacist care in all areas of patient care, including collaborative pharmacy practice;
(9) Compound and label drugs and drug devices;
(10) Proper and safe storage of drugs and devices;
(11) Maintain proper records;
(12) Provide patient counseling concerning the therapeutic value and proper use of drugs and devices;
(13) Order laboratory tests in accordance with drug therapy management; and
(14) Provide medication therapy management; and
(15) Prescribe of drugs, drug categories, or devices, excluding controlled substances, that are in accordance with the product’s federal Food and Drug Administration-approved labeling and that are limited to conditions for which a relevant patient medication history has been taken and:
(A) (i) Have a test that is used to guide diagnosis or clinical decision-making that is waived under the federal Clinical Laboratory Improvement Amendments of 1988 that indicates the existence of a condition that is minor and generally self-limiting for influenza; Group A Streptococcus Pharyngitis; SARS-COV-2 and RSV; or
(ii) In the professional judgment of the pharmacist, are patient emergencies; or
(iii) refill an expired prescription for an epinephrine injection device.
(B) The pharmacist shall, within 72 hours, notify the patient’s primary care physician, if identified, of the test result and the permissible drug, drug categories, or devices that are prescribed.
(C) A prescription dispensed or prescribed pursuant to this article is limited to up to a 30-day supply within a six-month period, if more than 10 days is prescribed or dispensed, then the pharmacist shall notify the primary care physician, if identified.
(D) The Board of Pharmacy shall establish approved protocols based on current practice guidelines for the above named CLIA-waived tests.
(E) The provision of this section may not be interpreted to require payment of the services provided by Medicaid, CHIP, or PEIA.
(b) A licensee meeting the requirements as promulgated by legislative rule may administer immunizations.
(c) The sale of any medicine, if the contents of its container, or any part thereof, taken at one time, are likely to prove poisonous, deleterious, or habit-forming is prohibited by any person other than a registered pharmacist, who shall take precautions to acquaint the purchaser of the nature of the medicine at the time of sale.
Adopted
Rejected